Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05160636 · ClinicalTrials.gov registry record
A Study to Look at the Health Outcomes of Patients With COVID-19 and Influenza
A clinical trial of COVID-19 and Influenza, sponsored by Pfizer.
- Active
- Registry status
- 999
- Enrollment target
- 1
- Study location
NCT05160636: Active study of COVID-19 and Influenza, sponsored by Pfizer.
NCT05160636 is a study of COVID-19 and Influenza that is active but no longer recruiting, run by Pfizer. The registered enrollment target is 999 participants, below the 38,462-participant average among 298 other COVID-19 trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05160636, a study of COVID-19 and Influenza, is active but no longer recruiting, sponsored by Pfizer.
- ACTIVE NOT RECRUITING
- Registry status
- 999 participants
- Enrollment target
- 1
- Study location
Study Summary
The main purpose of this study is to understand: * the symptoms of COVID-19 or influenza- health-related outcomes of people with COVID-19 or influenza (influenza only included in updated study analyses) * the potential effects of COVID-19 vaccines in people with COVID-19 This study will enroll participants who are: * 18 years or older * reported to have symptoms with tests that have confirmed illness. The tests can be taken at any of CVS pharmacy COVID-19 or influenza test sites. The study will collect vaccine history information from participants who are ready to take part in the study. Participant will be emailed a form with questions about their health related to COVID-19 or influenza during multiple follow-ups over a 6-month period.
Primary Outcome
To assess the change in HRQoL using EQ-5D-5L before COVID-19 or influenza and over a 6-month period following the test-confirmed COVID-19 or influenza.
Conditions Studied
Interventions
- BIOLOGICAL COVID-19 Vaccine
Study Locations (1)
New York
- Pfizer - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 999 participants |
| Start Date | 2022-01-31 |
| Est. Completion | 2026-02-28 |
What the registry record for NCT05160636 still lists
NCT05160636 is an observational study that tracks outcomes without assigning an intervention. The registered 999 participants enrollment target is mid-sized for trials with a published cap, below the 38,462-participant average among 298 other COVID-19 trials with a reported enrollment target (97% lower).
The record links to 3 conditions, with COVID-19 appearing as the primary indexed condition, and to 1 intervention - of which COVID-19 Vaccine is the first listed.
NCT05160636 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT05160636 about?
NCT05160636 is a clinical study titled "A Study to Look at the Health Outcomes of Patients With COVID-19 and Influenza". The main purpose of this study is to understand: * the symptoms of COVID-19 or influenza- health-related outcomes of people with COVID-19 or influenza (influenza only included in updated study analyses) * the potential effects of COVID-19 vaccines in people with COVID-19 This study will enroll par...
What is the current status of trial NCT05160636?
This trial is currently active not recruiting. The enrollment target is 999 participants. The study started on 2022-01-31. Estimated completion is 2026-02-28.
What conditions does trial NCT05160636 study?
This clinical trial studies the following conditions: COVID-19, Influenza, Coronavirus Disease 2019.
What interventions are being tested in trial NCT05160636?
The interventions under investigation include: COVID-19 Vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT05160636?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05160636 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for COVID-19
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05160636's enrollment target sits among peer trials
999 78th of 298 higher than 221 of 298 other COVID-19 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other COVID-19 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
CArdiac REhabilitation for Building Exertional heArt Rate for Chronotropic Incompetence in Long COVID-19
RECRUITING · NA
-
Arginine Replacement Therapy in COVID-19
RECRUITING · Phase 2
-
A Study to Learn About Variant-Adapted COVID-19 RNA Vaccine Candidate(s) in Healthy Children
RECRUITING · Phase 2
-
Cardiac Magnetic Resonance Tissue Characterization in COVID-19 Survivors
RECRUITING
-
COVID-19 Health Adjustments in Nutrition, General Wellness, and Exercise
RECRUITING
-
The Impact of COVID-19 on Maternal and Neonatal Outcomes
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02986048 · 999 participants
Proton Therapy Patient Registry
- NCT04703244 · 999 participants
Development of Patient Derived Xenografts (PDX) in Patients With Breast Cancer
- NCT00018044 · 1,000 participants
Study of Mycobacterial Infections
- NCT01036581 · 1,000 participants · NA
Advanced Functional and Structural MRI Techniques for Neuropharmacological Imaging
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI